Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks IPOs and placings
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
GSK unveils promising results from endometrial cancer trial
(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday. The FTSE 100 pharmaceuticals giant said the data, presented at the Society of Gynecologic Oncology's 2024 annual meeting on women's cancer, revealed significant advancements in overall survival (OS) and progression-free survival (PFS).
It said the trial was aiming to discern which patients with primary advanced or recurrent endometrial cancer could benefit from Jemperli plus chemotherapy, with or without the addition of 'Zejula', or niraparib, maintenance.
Part one examined dostarlimab plus standard-of-care chemotherapy, carboplatin-paclitaxel, followed by dostarlimab versus chemotherapy plus placebo.
GSK said part two evaluated dostarlimab plus standard-of-care chemotherapy, followed by dostarlimab plus niraparib as maintenance therapy versus chemotherapy plus placebo.
The results showed a 31% reduction in the risk of death and a 16.4-month improvement in median OS with dostarlimab plus chemotherapy compared to chemotherapy alone in the overall patient population.
Additionally, the addition of Zejula to dostarlimab maintenance following dostarlimab plus chemotherapy exhibited a 37% reduction in the risk of disease progression or death and a six-month enhancement in median PFS in the MMRp/MSS population.
The findings were significant as Jemperli plus chemotherapy emerged as the sole immuno-oncology combination demonstrating statistically significant and clinically meaningful OS in the overall endometrial cancer population.
It also underscored the potential benefit of the combination therapy, with or without niraparib, for patients with mismatch repair proficient (MMRp) or microsatellite stable (MSS) tumours, where approved immunotherapy-based regimens were currently lacking.
The company said the safety and tolerability profiles of dostarlimab plus carboplatin-paclitaxel and dostarlimab plus carboplatin-paclitaxel followed by dostarlimab plus niraparib were consistent with the known safety profiles of the individual medicines.
"The positive data presented today further show how dostarlimab-based regimens could benefit a broader set of patients with endometrial cancer," said GSK senior vice-president and global head of oncology research and development.
"The results we've seen to date comprise the growing body of evidence supporting the role of dostarlimab as the backbone of our immuno-oncology development programme.
"Our goal is to continue to identify ways to use dostarlimab alone and in combination with other therapies to help improve outcomes for patients with limited treatment options."
At 1140 GMT, shares in GSK were up 0.38% at 1,655.8p.
Reporting by Josh White for Sharecast.com.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity and Inclusion | Doing Business with Fidelity | Fidelity gender pay report | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Security | Statutory and Regulatory disclosures | Whistleblowing policy
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.